Metyrosine in psychosis associated with 22q11.2 deletion syndrome: case report.

Authors:
Carlo G Carandang
Carlo G Carandang
Dalhousie University
Canada

J Child Adolesc Psychopharmacol 2007 Feb;17(1):115-20

Dalhousie University, Halifax, Nova Scotia, Canada.

This report describes the use of metyrosine (Demser) in an adolescent male with psychosis associated with the 22q11.2 deletion syndrome (velocardiofacial syndrome; VCFS), diagnosed by fluorescence in situ hybridization (FISH). He presented with multiple features of 22q11.2 deletion syndrome, including ventricular septal defect, palatal abnormalities, speech and motor delays, attention deficits, mood lability, and psychosis. After a failed trial of an atypical antipsychotic to address the psychosis, metyrosine was initiated, with significant reduction of psychotic symptoms and mood lability. Metyrosine treatment allowed this youth to live at home and to attend school, after months of recurrent psychiatric hospitalizations. The successful treatment of metyrosine for psychosis associated with VCFS represents a first in psychiatry, where a known biochemical abnormality in a psychiatric disorder was corrected by a treatment that targets the biochemical pathway, leading to reduction of psychiatric symptoms and improvement of functioning.

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2006.0013DOI Listing
February 2007
465 Reads
4 Citations
2.933 Impact Factor

Article Mentions


Provided by Crossref Event Data
cambia-lens
Cambia-lens: Nasal Delivery
March 12, 2014, 8:00 pm EST

Publication Analysis

Top Keywords

22q112 deletion
12
psychosis associated
12
deletion syndrome
12
mood lability
8
associated 22q112
8
metyrosine psychosis
8
metyrosine
5
psychotic symptoms
4
reduction psychotic
4
initiated reduction
4
psychosis metyrosine
4
metyrosine initiated
4
lability metyrosine
4
treatment allowed
4
allowed youth
4
metyrosine treatment
4
address psychosis
4
youth live
4
symptoms mood
4
failed trial
4

Similar Publications